Following the knockout of STAT3, a significant inhibition in the drug persistence of CML cells was observed, leading to an increased sensitivity of persistent CML cells to TKI therapy upon inhibition of STAT3 with small molecule inhibitors. The gene discussed is STAT3; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.